KCNQ1
Reactivity: Human
WB, IHC, IP, ICC, IF, AA
Host: Mouse
Monoclonal
N37A-10 (Formerly S37A-10)
Atto 594
Application Notes
Peptide ELISA: 1/16000. Western Blot: Use at 1-3 μg/mL. Approx.60 kDa band observed in Human Heart lysates (calculated MW of 61.0 kDaaccording to NP_861463.1). An additional band of unknown identity was also consistently observed at 20 kDa. Thisband was successfully blocked by incubation with the immunizing peptide. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
0.5 mg/mL
Buffer
Tris-saline, pH 7.3 containing 0.02 % Sodium Azide as preservative and 0.5 % BSA as stabilizer.
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Target
KCNQ1
(Potassium Voltage-Gated Channel, KQT-Like Subfamily, Member 1 (KCNQ1))
This gene encodes a protein for a voltage-gated potassium channel required for the repolarization phase of the cardiac action potential. The gene product can form heteromultimers with two other potassium channel proteins, KCNE1 and KCNE3. Mutations in this gene are associated with hereditary long QT syndrome, Romano-Ward syndrome, Jervell and Lange-Nielsen syndrome and familial atrial fibrillation. The gene is located in a region of chromosome 11 that contains a large number of contiguous genes that are abnormally imprinted in cancer and the Beckwith-Wiedemann syndrome. Two alternative transcripts encoding distinct isoforms have been described (from EntrezGene).Synonyms: IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1, KCNA8, KCNA9, KQT-like 1, KVLQT1, Potassium voltage-gated channel subfamily KQT member 1, Voltage-gated potassium channel subunit Kv7.1